Pα+ Psychedelic Bulletin #153: MindMed Scraps Microdosing Program; Eagerly Anticipated Ibogaine Study Publishes; Compass Collaborates with Greenbrook; Gilgamesh’s GM-1020 Readout; and more…
- MindMed Scraps LSD Microdosing Program
- Eagerly Anticipated Ibogaine Study Publishes
- Compass Pathways Announces 3-Year Research Collaboration with Interventional Psychiatry Chain, Greenbrook TMS
- Gilgamesh’s GM-1020 Shows Antidepressant-Like Activity in Mice
- Cybin Shares Topline Data Suggesting Deuterated DMT Candidates Can Be Bridged; IM Route Possible
- atai Shares Morsel of EMP-01 Data in Phase I Readout
- VA Vows to Fund Psychedelic Research
- DEA Establishes Initial 2024 Aggregate Production Quotas for Psychedelics
- In Case You Missed It
- Pα+ Psychedelic Patent Analysis (November 2023)
- MAPS PBC Closes $100m Series A, Rebrands to Lykos Therapeutics
- Kentucky’s $42m Ibogaine Funding Appears Dead in the Water
- atai Life Sciences Makes $50m Investment in Beckley Psytech
- The Obscure Advisory Panel Blocking Dozens of Psychedelic Studies in California
- Other Headlines
This Issue is a relatively long one, as it’s something of a catch-up for the holiday period. We look at psychedelic drug development news from the likes of MindMed, Gilgamesh and atai as well as news stories concerning the VA and DEA.
We also review and summarise our recent long-read coverage, as well as provide updates to some of those stories.
Companies, organisations and drug candidates mentioned in this Bulletin include: MindMed, MM-120, Stanford, MISTIC, Ambio Life Sciences, Compass Pathways, Greenbrook TMS, Cybin, Gilgamesh Pharmaceuticals, GM-1020, AstraZeneca, AZD6765, rapastinel, Allergan, CYB004, SPL028, Small Pharma, dDMT, atai Life Sciences, R-MDMA, EMP-01, IDEA-1, EmpathBio, Lykos Therapeutics, Beckley Psytech, Tryp Therapeutics, Clarion Clinics, BetterLife Pharma...
Join Today
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and research.
- Regular Bulletins featuring news, analysis, and research
- Articles and deep dives across psychedelic drug development, policy, and research
- Exclusive interviews with researchers, executives, and policymakers
- Bespoke resources and tools including the Psychedelic Bill Tracker
- Quarterly video briefings and slide decks